CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to GILD

Sacituzumab Govitecan (SG)

Phase 3
Gilead Sciences, Inc. (GILD)

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Feb '27
GILDPhase 2

Sacituzumab Govitecan (SG) Phase 2 Est. Readout

Sacituzumab Govitecan (SG)
Feb 2027~
CT.gov
00%
Dec '26
GILDPhase 2

Sacituzumab Govitecan (SG) Phase 2 Est. Readout

Sacituzumab Govitecan (SG)
Dec 2026~
CT.gov
00%
Competitive Landscape

1 competitor in Extensive Stage Small Cell Lung Cancer (ES-SCLC)

View Full Landscape
Drug Information

Target Indication

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Clinical Trial

NCT06801834

Last updated: 1/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.